Industry News

Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human Threat

11/26/2020

Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Adagio Therapeutics, Inc., today pre-published in vitro and in vivo data demonstrating its lead antibody candidate, ADG2, shows similar or higher potency against SARS-CoV-2 compared to monoclonal antibodies (mAbs) in clinical development, while also uniquely offering broad neutralization against a range of sarbecoviruses that pose a threat to…

Read More

Tough yet flexible: Biologically inspired adhesive may improve fetal surgery

11/25/2020

Excerpt from the Article: In children with spina bifida, the neural tube that forms the spinal cord and brain doesn’t close during early prenatal development. That leaves the nerves of the spinal cord exposed to potential damage from fetal movement and the surrounding amniotic fluid. While surgeons can repair spina bifida soon after birth, the…

Read More

Mammography AI Tool Cleared This Year Improves Breast Cancer Detection

11/25/2020

Excerpt from the Article: Adding artificial intelligence (AI) to mammography interpretation can help radiologists catch more cancers, according to a new study using a tool awarded U.S. Food & Drug Administration 510(k) clearance earlier this year. Currently, the body of literature around the effectiveness of AI with mammography is small because the use of the…

Read More

Fluidigm COVID-19 Community Connect Program Builds a Network of Testing Partners to Increase Access of Saliva-Based SARS-CoV-2 Testing for Communities

11/25/2020

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced COVID-19 Community Connect, a program to link federal, state and local governmental entities, public health agencies, academic institutions, workforces, individuals and…

Read More

BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence

11/24/2020

Excerpt from the Press Release: SAN RAFAEL, Calif. and TORONTO, Nov. 17, 2020 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications…

Read More

The FDA’s Digital Health Center Of Excellence: Why It Matters And What It Means To You

11/23/2020

Excerpt from the Article: Last month, the US Food and Drug Administration (FDA) launched the Digital Health Center of Excellence (DHCoE), bolstering the shift toward digital that the healthcare industry has already been embracing. Investment in digital health is at an all-time high. The market cap created from nine IPOs in 2019 from companies in…

Read More

AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

11/23/2020

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced positive new data across its clinical programs in Gaucher disease type 1, Fabry disease and cystinosis, further reinforcing the potential of ex vivo lentiviral…

Read More

Hope Biosciences Stem Cell Research Foundation Selects Phlexglobal to Support Rapid, Compliant Investigational New Drug Application for COVID-19 Therapy

11/19/2020

Excerpt from the Press Release: Phlexglobal, a leading innovative technology and services provider for the life sciences industry, today announces that Hope Biosciences Stem Cell Research Foundation has selected Phlexglobal’s advanced SaaS solution, PhlexSubmission, to enhance the efficiency and quality of its eCTD submissions process. As an organization dedicated to advancing research through innovative protocols…

Read More

Werewolf Therapeutics Appoints Dr. Randi Isaacs as Chief Medical Officer

11/18/2020

Excerpt from the Press Release: CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ — Werewolf Therapeutics, Inc., an oncology biotherapeutics company developing next-generation, transformative cancer therapeutics, today announced the appointment of Randi Isaacs, M.D., as Chief Medical Officer. Dr. Isaacs brings to the Werewolf team more than 20 years’ experience as a hematologist and oncologist driving clinical…

Read More

Novel insights on cellular suicide could provide new avenues for cancer therapies

11/15/2020

Excerpt from the Article: Several years ago, biologist Denise Montell, a distinguished professor at UC Santa Barbara, found that sometimes cells survive after what was considered the critical step in cellular suicide. Now, she and her lab have identified two key factors involved in this remarkable recovery. The findings, published in Nature Communications, indicate that…

Read More